Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase
This study suggests CGFSVNLC achieves codelivery, selective targeting, and enhancing the synergistic effect of GF and SV for inducing HepG2 cell death. Mechanistically, CGFSVNLC inhibits key cascades implicated in MDR and HepG2 cell survival. CGFSVNLC is promising for overcoming drug resistance mechanisms and improving therapeutic outcomes against HepG2 cells.
Authors
- Gamaleldin I. Harisa (ORCID: https://orcid.org/0000-0002-7988-4421)
- Sabry Mohamed Attia (ORCID: https://orcid.org/0000-0001-8560-8944)
- Sultan Alamri (ORCID: https://orcid.org/0000-0001-8429-6598)
- Ahmed H.H. Bakheit (ORCID: https://orcid.org/0000-0002-0445-1357)
- Hanadi H. Asiri (ORCID: https://orcid.org/0009-0005-1649-7749)
- Abdulrahman A Alluhaidan
- Riyad F Alzhrani
Institutions
- King Saud University (SA)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2024-08-26
- DOI
- https://doi.org/10.32604/or.2024.053337
- Citations
- 1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.36